Peptide profile · Immune
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Human cationic antimicrobial protein-18 (hCAP-18) precursor and its synthetic derivative SAAP-148 — a next-generation 24-amino-acid cathelicidin-based peptide with broad-spectrum bactericidal activity against multidrug-resistant ESKAPE pathogens including MRSA biofilms, superior potency to its parent fragment LL-37, and retained efficacy under physiological salt and plasma conditions
Molecular formula
hCAP-18: ~18 kDa precursor protein (170 AA); SAAP-148: C155H253N49O31 (approximate), MW 3,267.1 Da
- CAS number
- Not assigned (SAAP-148 and OP-145 are novel synthetic derivatives)
- PubChem
- 171391899 (SAAP-148); hCAP-18 precursor: UniProt P49913
- Developed · hCAP-18 characterized: 1995; SAAP-148: 2018 (Science Translational Medicine publication); OP-145: 2009-2015 (clinical trials)
- Endogenous Human Immune System, Naturally occurring; clinical development by various biotech companies
Amino acid sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES0.5mg
Every documented dose level
| Phase | Dose | Frequency |
|---|---|---|
| 2 weeks | 0.5 mg/mL drops (about 100 microliters per application) | Twice daily |
Best for research into next-generation antimicrobials against multidrug-resistant infections & topical antimicrobial development for wound infections with biofilm involvement
Best for
Research into next-generation antimicrobials against multidrug-resistant infections
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on research into next-generation antimicrobials against multidrug-resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Topical antimicrobial development for wound infections with biofilm involvement
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on topical antimicrobial development for wound infections with biofilm involvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding vitamin D-cathelicidin innate immune axis for immune optimization
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on understanding vitamin d-cathelicidin innate immune axis for immune optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of anti-biofilm therapeutics for chronic device-related and wound infections
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on development of anti-biofilm therapeutics for chronic device-related and wound infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
- Known hypersensitivity to cathelicidin-derived peptides or formulation components
- Pregnancy and breastfeeding — insufficient reproductive safety data for synthetic derivatives
- Active autoimmune conditions involving cathelicidin dysregulation (e.g., rosacea, psoriasis) — exogenous cathelicidin peptides may exacerbate inflammation
- Severe systemic immunodeficiency without medical supervision — immune modulation effects may be unpredictable
Use with caution if
- You are taking other medications—discuss potential interactions with your healthcare provider
- You have a history of liver or kidney disease
- You are elderly or have multiple medical conditions
- You are planning surgery in the near future—inform your surgeon about Cathelicidin (hCAP-18 / Synthetic Derivatives) use
- You have any chronic health conditions that require regular monitoring
Not sure?
Compare Cathelicidin (hCAP-18 / Synthetic Derivatives) with similar peptides to find the best fit for your goals.
Route
Cathelicidin (hCAP-18 / Synthetic Derivatives) is administered Topical application (primary research route)—no injection required
Best sites
- Not applicable—this is not an injectable formulation
The Cathelicidin (hCAP-18 / Synthetic Derivatives) injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.
3 common side effects · 2 serious
Cathelicidin peptides (natural and synthetic) are not FDA-approved.
Human data are limited: in a randomized Phase IIa trial, ear drops of the LL-37-derived peptide OP-145 were safe and well tolerated in chronic middle-ear infection . Animal studies demonstrate broad-spectrum antimicrobial activity without systemic toxicity at therapeutic concentrations.
However, concern exists regarding immunological tolerance—cathelicidin derivatives can trigger innate immune activation and inflammatory responses at high concentrations.
The peptide's mechanism on immune cells is incompletely understood in humans, and effects on chronic immune signaling, tolerance development, or off-target immune activation remain uncharacterized.
Bacterial resistance development to cathelicidin-based therapeutics is theoretically possible but not yet documented clinically.
Evidence is mostly from in vitro antimicrobial activity assays, animal infection models, and preclinical immune cell studies.
Human data are limited to small trials of synthetic derivatives, such as a dose-finding study and a randomized Phase IIa trial of OP-145 ear drops (34 patients; treatment success 47% vs 6% on placebo) .
Published research focuses on mechanism of antimicrobial action rather than safety profiling or tolerability in human use.
Common side effects · experienced by some users
Local application site irritation
Mild redness, warmth, and stinging at the topical application site. Reflects the peptide's interaction with skin cells and local immune activation.
Management
Use appropriate formulation vehicle (hypromellose ointment). Apply to wound bed rather than intact skin. Monitor and reduce concentration if irritation is excessive.
Local inflammatory response
Transient increase in local inflammation including mild swelling and erythema around the treated area as immune cells are recruited via FPR2/ALX receptor activation.
Management
This is expected and generally beneficial — indicates immune cell recruitment to the infection site. Monitor for excessive inflammation. Should resolve within 24-48 hours.
Mild wound exudate increase
Increased wound exudate in the first 24-48 hours of treatment as biofilm disruption releases bacterial contents and immune infiltration increases.
Management
Change wound dressings as needed. Increased exudate initially is expected with biofilm disruption. Should normalize within 2-3 days as bacterial load decreases.
Serious side effects
Hemolytic activity at supratherapeutic doses
At concentrations exceeding 50 µM, SAAP-148 demonstrates hemolytic activity against human red blood cells. This is the primary dose-limiting toxicity identified in preclinical studies.
Management
Maintain dosing within the established therapeutic window (<25.6 µM for topical, <50 µM absolute maximum). Monitor for signs of hemolysis if systemic exposure occurs. This toxicity is concentration-dependent and avoidable with proper dosing.
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Cathelicidin (hCAP-18 / Synthetic Derivatives)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Cathelicidin (hCAP-18 / Synthetic Derivatives) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- SafeVitamin D3 (directly upregulates CAMP gene expression and endogenous cathelicidin production through VDR activation — synergistic immune enhancement) — May be used together under medical guidance.
- SafeConventional antibiotics (cathelicidin derivatives synergize with rifampicin, vancomycin, and gentamicin against biofilm infections — lowering effective antibiotic doses) — May be used together under medical guidance.
- SafeSilver wound dressings (complementary antimicrobial mechanisms — physical membrane disruption plus ion-mediated protein denaturation) — May be used together under medical guidance.
With medications
- CautionHigh concentrations of divalent cations (Mg²⁺, Ca²⁺) in formulations — may reduce electrostatic membrane binding of cationic cathelicidin peptides — Use with caution—discuss with your healthcare provider.
- CautionAnionic surfactants or high-concentration albumin solutions — may sequester cationic peptides and reduce bioavailability — Use with caution—discuss with your healthcare provider.
- CautionImmunosuppressive medications without supervision — cathelicidin derivatives promote immune activation that may conflict with immunosuppressive goals — Use with caution—discuss with your healthcare provider.
With supplements
- SafeMultivitamins — Generally safe to take alongside Cathelicidin (hCAP-18 / Synthetic Derivatives). Space doses apart if taking oral formulations to ensure optimal absorption.
- SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Moderate human trials · first signs hours 0-24 (first application)
Evidence level
Moderate human trials
(Phase 1-2)
80/100
Regulatory status
Research compound
Onset of effects
Rapid
(hours to days)
How it works
Cathelicidin (LL-37) is a natural antimicrobial peptide your immune cells produce to kill bacteria, viruses, and fungi.
It also reduces inflammation and promotes wound healing, making it a multi-functional defender of your health.
The deeper mechanism
Cathelicidin is a 37-amino acid cationic antimicrobial peptide synthesized primarily by neutrophils, epithelial cells, and other immune cells from the precursor hCAP18 following proteolytic cleavage.
It exhibits broad-spectrum antimicrobial activity through multiple mechanisms: membrane disruption via formation of α-helical structures that insert into bacterial and fungal membranes, specific binding to lipopolysaccharides and lipoteichoic acids, and intracellular targeting of nucleic acids.
Beyond antimicrobial functions, cathelicidin modulates innate immunity through TLR9 and G-protein coupled receptor signaling, promoting chemotaxis of immune cells, enhancing phagocytosis, and reducing pro-inflammatory cytokine production via NF-κB pathway suppression.
What to expect
Hours 0-24 (first application)
What you might notice
- Rapid bactericidal activity begins within 30 minutes of application
- Mild local redness and warmth at the application site
- Increased wound exudate as biofilm matrix is disrupted
- Visible reduction in wound bed bacterial burden (clinical observation)
What's normal
- SAAP-148 achieves >99% killing of planktonic bacteria within 30 minutes
- Biofilm disruption releases trapped bacteria and debris — increased exudate is expected
- Local immune cell recruitment via FPR2/ALX begins within hours
- Inflammatory response indicates active immune engagement
What's next
- Continue daily application per research protocol
- Biofilm eradication requires 2-4 hours of sustained exposure
- Monitor wound appearance and exudate characteristics
- Re-evaluate at 48-72 hours for evidence of reduced bacterial burden
Days 2-7 (active treatment phase)
What you might notice
- Progressive reduction in wound infection signs (less erythema, reduced exudate, decreased odor)
- Appearance of healthy granulation tissue as bacterial burden decreases
- Reduced local inflammation as infection is controlled
- Evidence of wound edge contraction and early epithelialization
What's normal
- Biofilm eradication and bacterial clearance typically require 3-7 days of repeated application
- Wound healing acceleration through keratinocyte migration stimulation and VEGF-mediated angiogenesis
- Progressive improvement in wound bed appearance
- Immune modulation shifts from pro-inflammatory (pathogen clearance) to pro-resolution (healing)
What's next
- Continue treatment through the full planned protocol duration
- Assess need for continued application based on wound culture results
- Monitor for any emerging resistance (extremely unlikely with membrane-targeting mechanism)
- Consider transition to maintenance dosing or conventional wound care once infection resolves
Week 2-4 (resolution and healing)
What you might notice
- Wound infection fully resolved with negative cultures
- Active wound healing with healthy granulation and epithelialization
- Reduced need for continued antimicrobial treatment
- Overall improvement in wound closure and tissue quality
What's normal
- Cathelicidin-derived peptides support the full healing cascade from infection clearance to tissue repair
- Low resistance emergence — multi-target membrane mechanism prevents bacterial adaptation
- Transition from antimicrobial to predominantly wound-healing effects
- Effects on immune cell recruitment and function continue supporting tissue regeneration
What's next
- Transition to standard wound care once infection is cleared
- Monitor for any recurrence at the treatment site
- Document outcomes for research protocol analysis
- Consider vitamin D optimization to support endogenous cathelicidin production long-term
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Cathelicidin (hCAP-18 / Synthetic Derivatives) over time
- Reduction in symptom frequency or severity
Signs it's working
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results?
Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
How is this cathelicidin entry different from the LL-37 entry on this site?
LL-37 is the 37-amino-acid mature peptide cleaved from the cathelicidin precursor protein hCAP-18 by neutrophil proteinase 3. This cathelicidin entry focuses on the broader cathelicidin system — the hCAP-18 precursor protein, the vitamin D-regulated CAMP gene, and especially the next-generation synthetic derivatives SAAP-148 and OP-145 that were engineered to overcome LL-37's key limitation of losing antimicrobial activity under physiological conditions. SAAP-148 retains full potency in human plasma and physiological salt, while LL-37 does not.
What makes SAAP-148 better than LL-37 for clinical development?
LL-37's major translational barrier is that it loses most of its antimicrobial activity in the presence of physiological salt concentrations (150 mM NaCl), serum proteins, and human plasma. SAAP-148 was specifically engineered at Leiden University Medical Center to solve this problem — through optimization of charge distribution (+11 vs LL-37's +6) and hydrophobic core stability, SAAP-148 maintains full bactericidal and anti-biofilm activity under physiological conditions. This means the concentrations that work in the lab actually work in human wound environments.
Why is vitamin D important for cathelicidin?
The CAMP gene that encodes the cathelicidin precursor hCAP-18 has a vitamin D response element (VDRE) in its promoter region. When 1,25-dihydroxyvitamin D3 (active vitamin D) binds the vitamin D receptor, it directly upregulates CAMP gene transcription in neutrophils, macrophages, and epithelial cells. This means circulating 25-hydroxyvitamin D levels directly influence antimicrobial peptide production — explaining why vitamin D deficiency is associated with increased susceptibility to infections, particularly tuberculosis and respiratory infections.
Can bacteria develop resistance to cathelicidin-derived peptides?
Resistance development is extremely unlikely with cathelicidin-derived peptides because they target the fundamental physical structure of bacterial membranes rather than a specific protein or metabolic pathway. The multi-target membrane disruption mechanism — involving electrostatic binding, lipid insertion, pore formation, and membrane depolarization — would require bacteria to completely restructure their membrane architecture, which is incompatible with viability. Serial passage experiments with SAAP-148 show no significant resistance development even after extended exposure.
What happened with the OP-145 clinical trial?
OP-145 (also known as P60.4Ac), a 24-amino-acid cathelicidin-derived peptide with a +7 net charge, was evaluated in a Phase I/II clinical trial for chronic suppurative otitis media (CSOM) — chronic ear infections involving biofilms. The trial demonstrated that OP-145 ear drops were safe, well-tolerated, and showed efficacy against chronic biofilm infections that had failed conventional antibiotic therapy. This trial represented the first clinical validation of a synthetic cathelicidin derivative for treating human biofilm infections.
Is cathelicidin the same as the antimicrobial peptide found in sweat?
Cathelicidin (LL-37 cleaved from hCAP-18) is indeed one of several antimicrobial peptides found in human sweat, alongside dermcidin and human beta-defensins. However, cathelicidin is much more broadly expressed — it is produced by neutrophils (stored in specific granules), macrophages, epithelial cells of the skin, respiratory tract, urinary tract, and gastrointestinal tract. Its expression in these barrier tissues makes it one of the body's first-line defenders against invading pathogens, well before adaptive immune responses engage.
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Cathelicidin (hCAP-18 / Synthetic Derivatives), on one page.
Cathelicidin (hCAP-18 / Synthetic Derivatives) dosing protocol